

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (currently amended) ~~A~~ The composition according to claim 16, comprising a protein in crystalline form having unit cell dimensions, +/- 5%, of $a=88.80\text{\AA}$ $b=88.80\text{\AA}$ and $c=174.99\text{\AA}$, $\alpha=\beta=\gamma=90^\circ$ ~~wherein at least a portion of the protein has at least 90% identity with residues 16-314 of SEQ. ID No. 1.~~
2. (cancelled)
3. (cancelled)
4. (currently amended) A composition according to claim ~~1~~ 16 wherein the protein diffracts X-rays for a determination of structure coordinates to a resolution ~~greater of a value equal to or less~~ greater of a value equal to or less than 3.0 Angstroms.
5. (currently amended) ~~A~~ The composition according to claim 16 wherein the protein crystal has a crystal lattice in a $P4_122$ space group.
6. (currently amended) A method for forming a crystal of a protein comprising:
 forming a crystallization volume comprising a precipitant solution and a protein ~~wherein at least a portion of the protein has at least 90% identity with that consists of residues 16-314-1-314 of SEQ. ID No. 1; and~~
 storing the crystallization volume under conditions suitable for ~~crystal~~ crystal formation of ~~the a protein crystal; and~~

~~forming a crystalline form of the protein having unit cell dimensions, +/- 5%, of
a=88.80Å b=88.80Å and c=174.99Å, $\alpha=\beta=\gamma=90$.~~

7. (cancelled)

8. (cancelled)

9. (currently amended) A method according to claim 6 wherein the protein diffracts X-rays for a determination of structure coordinates to a resolution greater of a value equal to or less than 3.0 Angstroms.

10. (original) A method according to claim 6 wherein the protein crystal has a crystal lattice in a P4₁22 space group.

Claims 11-15. (cancelled)

16. (new) A composition comprising a protein in crystalline form wherein the protein consists of residues 1-314 of SEQ. ID No. 1.

17. (new) The method according to claim 6 wherein the protein crystal has a crystal lattice having unit cell dimensions, +/- 5%, of a=88.80Å b=88.80Å and c=174.99Å, $\alpha=\beta=\gamma=90$.

18. (new) The method according to claim 6 comprising:
diffracting the protein crystal to produce a diffraction pattern; and
solving the structure of the protein crystal from the diffraction pattern.

19. (new) A composition comprising a protein consisting of residues 1-314 of SEQ. ID No. 1.

20. (new) The method according to claim 18 wherein the protein crystal has unit cell dimensions, +/- 5%, of $a=88.80\text{\AA}$ $b=88.80\text{\AA}$ and $c=174.99\text{\AA}$, $\alpha=\beta=\gamma=90$.

21 (new). The method according to claim 18, the method further comprising:
performing rational drug design using the solved structure; and
identifying an entity that associates with the protein.

22. (new) The method according to claim 21 further comprising selecting one or more entities based on the rational drug design and contacting the selected entities with the protein.

23. (new) The method according to claim 21 further comprising measuring an activity of the protein when contacted with the one or more entities.